DarioHealth Introduces iPhone 7, iPhone 8, and iPhone X Compatible Smart Glucose Meter to the Australian Market

Market Penetration "Down Under" Expected to Increase as Lightning® Enabled Version is Now Available

CAESAREA, Israel, Jan. 17, 2018 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO), a leading global digital health company with mobile health and big data solutions, today announced it has launched the Lightning®-enabled version of the acclaimed Dario™ Blood Glucose Monitoring System in the Australian market. The Lightning®-enabled device ensures that Apple consumers "Down Under" will be able to connect the Dario smart glucose meter to the latest iOS handsets, including the brand-new iPhone X.

By some estimates, Apple iOS has over 55% market share in Australia, and DarioHealth expects to increase revenues in the Australian market with this launch. In addition, Dario blood glucose test strips can be found in major pharmacies across Australia, especially in New South Wales and Victoria, where it can be found in many of the leading pharmacies, including Priceline Pharmacy, Amcal Chemist, and Terry White Chemists.

Erez Raphael, Chairman and CEO of DarioHealth, commented: "We are happy to confirm that we are recommitting ourselves to the Australian market. Over the past few months, we have been working tirelessly to get the TGA (Therapeutic Goods Administration) Mark so we can cater to the Australian market and help people with diabetes to manage their disease with the most up-to-date technology Dario has to offer. We look forward to continuing our mission of simplifying diabetes management in all of our markets globally."

This news continues to highlight DarioHealth's agility and ability to operate around the world. The Australian market is the second market this month to receive the Dario Lightning®-enabled device, after our successful launch last week in the U.K.  Germany is the next market expected to launch the Dario Smart Glucose Meter for iPhone 7, iPhone 8, and iPhone X. In the U.S. market, the Dario Lightning®-enabled device is still under review by the U.S. Food and Drug Administration (F.D.A.), and the Company expects to hear about possible clearance during the next few months.

About DarioHealth Corp.

DarioHealth Corp. is a leading global digital health company serving tens of thousands of users with dynamic mobile health solutions. We believe people deserve the best tools to manage their treatment, and harnessing big data, we have developed a unique way for our users to analyze and personalize their diabetes management. With our smart diabetes solution, users have direct access to track and monitor all facets of diabetes, without having the disease slow them down. The acclaimed Dario™ Blood Glucose Monitoring System all-in-one blood glucose meter and native smartphone app give users an unrivaled method for self-diabetes management. DarioHealth is headquartered in Caesarea, Israel with an office in New York. For more information, visit http://mydario.investorroom.com/.

Cautionary Note Regarding Forward-Looking Statements

This news release and the statements of representatives and partners of DarioHealth Corp. (the "Company") related thereto contain or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as "plan," "project," "potential," "seek," "may," "will," "expect," "believe," "anticipate," "intend," "could," "estimate," or "continue" are intended to identify forward-looking statements. For example, when the Company describes that it believes it will be able to increase Australian-driven revenues and achieve greater market penetration, begin Lightning®-enabled device sales in Germany and in the United States in the future, and that it expects to hear from the F.D.A. about possible clearance over the next few months, it is using forward-looking statements. Readers are cautioned that certain important factors may affect the Company's actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect the Company's results include, but are not limited to, regulatory approvals, product demand, market acceptance, impact of competitive products and prices, product development, commercialization or technological difficulties, the success or failure of negotiations and trade, legal, social and economic risks, and the risks associated with the adequacy of existing cash resources. Additional factors that could cause or contribute to differences between the Company's actual results and forward-looking statements include, but are not limited to, those risks discussed in the Company's filings with the U.S. Securities and Exchange Commission. Readers are cautioned that actual results (including, without limitation, the timing for and results of the Company's commercial and regulatory plans for Dario™) may differ significantly from those set forth in the forward-looking statements. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.

DarioHealth Corporate Contact:Shmuel Herschberg, Marketing Director, shmuel@mydario.com, +1-914-775-5548

DarioHealth Public Relations Contact:Terese Kelly, Rosica PR, terese@rosica.com, +1-201-843-5600

DarioHealth Investor Relations Contact: Westwicke Partners, Dario@Westwicke.com,


SOURCE DarioHealth Corp.

Did you like this article?